Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
CC transcript
GENEREX BIOTECHNOLOGY CORP (GNBT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SEC STAFF ACTION Form SEC STAFF ACTION - SEC Staff Action: ORDER
10/10/2023 SEC STAFF ACTION Form SEC STAFF ACTION - SEC Staff Action: ORDER
01/30/2023 REVOKED Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]:
11/01/2021 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
07/23/2021 8-K Quarterly results
07/21/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
06/21/2021 10-Q Quarterly Report for the period ended April 30, 2021
06/14/2021 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/12/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
03/17/2021 10-Q Quarterly Report for the period ended January 31, 2021
02/23/2021 8-K Quarterly results
02/19/2021 8-K Quarterly results
02/10/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
12/21/2020 10-Q Quarterly Report for the period ended October 31, 2020
12/17/2020 8-K/A Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "The Extension Agreement signed December 15, 2020",
"The Letter requesting more time for payment signed December 14, 2020"
12/17/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "The Extension Agreement signed December 15, 2020"
12/15/2020 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
11/25/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "INDEMNITY",
"INDEMNITY"
11/19/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "The Ii-Key Innovative Flu Vaccine Development Agreement signed November 13, 2020",
"Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine"
11/18/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "The Ii-Key Innovative Vaccine Development Agreement signed November 13, 2020",
"Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform"
11/13/2020 10-K Annual Report for the period ended July 31, 2020
11/05/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Framework Agreement on Cooperative Development of Coronavirus Peptide Vaccine signed October 30, 2020",
"Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines"
10/29/2020 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
10/09/2020 8-K Quarterly results
09/25/2020 8-K Quarterly results
09/24/2020 8-K Quarterly results
09/21/2020 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/18/2020 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/15/2020 EFFECT Form EFFECT - Notice of Effectiveness:
09/15/2020 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy